HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain.

AbstractOBJECTIVE:
To test the adjuvant use of the combination of N-palmitoylethanolamine and transpolydatin in the medical treatment of endometriotic pain.
STUDY DESIGN:
We enrolled 47 patients admitted to the Outpatient Endometriosis Care Unit of Ferrara University from January 2011 to December 2011. They were divided into two groups according to the endometriosis site (group A: recto-vaginal septum; group B: ovary). One tablet, containing 400 mg of micronized N-palmitoylethanolamine plus 40 mg transpolydatin, was administered twice daily on a full stomach for 90 days. Each patient was requested to grade the severity of dysmenorrhea, chronic pelvic pain, dyspareunia and dyschezia using a 0-10 cm visual analogic scale prior to beginning treatment (T0), after 30 days (T1), 60 days (T2) and 90 days (T3). The continuous and categorical variables were compared, respectively, using Student's t-test and the chi-square test. Analysis of variance for repeated measures was used to verify the reduction of endometriotic pain.
RESULTS:
The intensity of endometriotic pain decreased significantly for both groups (p<0.0001). The efficacy of drug treatment was significant after 30 days. Pain intensity decreased equally in the two groups except for dysmenorrhea, which was reduced more rapidly in group B.
CONCLUSIONS:
The combination of N-palmitoylethanolamine and transpolydatin reduced pain related to endometriosis irrespective of lesion site. It had a marked effect on chronic pelvic pain determined by deep endometriosis and on dysmenorrhea correlated to ovarian endometriosis.
AuthorsEmilio Giugliano, Elisa Cagnazzo, Ilaria Soave, Giuseppe Lo Monte, Jean Marie Wenger, Roberto Marci
JournalEuropean journal of obstetrics, gynecology, and reproductive biology (Eur J Obstet Gynecol Reprod Biol) Vol. 168 Issue 2 Pg. 209-13 (Jun 2013) ISSN: 1872-7654 [Electronic] Ireland
PMID23415738 (Publication Type: Journal Article)
CopyrightCopyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Amides
  • Anti-Inflammatory Agents, Non-Steroidal
  • Contraceptives, Oral, Combined
  • Drug Combinations
  • Endocannabinoids
  • Ethanolamines
  • Glucosides
  • Palmitic Acids
  • Stilbenes
  • palmidrol
  • polydatin
Topics
  • Adult
  • Amides
  • Anti-Inflammatory Agents, Non-Steroidal (chemistry, therapeutic use)
  • Chronic Pain (etiology, prevention & control)
  • Contraceptives, Oral, Combined (therapeutic use)
  • Drug Combinations
  • Drug Therapy, Combination
  • Dysmenorrhea (etiology, prevention & control)
  • Endocannabinoids (therapeutic use)
  • Endometriosis (drug therapy, immunology, physiopathology)
  • Ethanolamines (therapeutic use)
  • Fascia (drug effects, immunology)
  • Female
  • Female Urogenital Diseases (drug therapy, immunology, physiopathology)
  • Glucosides (chemistry, therapeutic use)
  • Humans
  • Middle Aged
  • Ovarian Diseases (drug therapy, immunology, physiopathology)
  • Pain Measurement
  • Palmitic Acids (therapeutic use)
  • Pelvic Pain (etiology, prevention & control)
  • Prospective Studies
  • Stereoisomerism
  • Stilbenes (chemistry, therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: